Nothing about the Lexicon Pharmaceuticals (LXRX) story has been easy or conventional, and that includes the company's somewhat surprising decision to sell off its sole commercial product, Xermelo, and effectively return itself to a pre-revenue stage with a single asset in the clinic (LX9211 for pain).
The decision to monetize Xermelo makes some sense, though there are some curious aspects to the deal, and I can't say it dramatically increases the risk profile. That said, Lexicon's funding situation is still less than ideal, and the company's decision to put all of its near-term eggs in the pain basket is a risky one, given the industry's experience with pain as a therapeutic target. While there's some speculative appeal here again, everything rides on the clinical success of LX9211 at this point.
Lexicon Pharmaceuticals Returning To Its Pre-Revenue Biotech Days
No comments:
Post a Comment